Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves' Orbitopathy (EUGOGO)..

Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828.

2.

Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.

Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F.

J Endocrinol Invest. 2015 Apr;38(4):481-7. doi: 10.1007/s40618-015-0257-z. No abstract available.

3.

Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?

Daumerie C, Boschi A, Perros P.

Eur Thyroid J. 2012 Jul;1(2):105-9. doi: 10.1159/000338038.

4.

Medical management of thyroid eye disease.

Yang DD, Gonzalez MO, Durairaj VD.

Saudi J Ophthalmol. 2011 Jan;25(1):3-13. doi: 10.1016/j.sjopt.2010.10.001.

5.

Radioiodine thyroid ablation in graves' hyperthyroidism: merits and pitfalls.

Nwatsock JF, Taieb D, Tessonnier L, Mancini J, Dong-A-Zok F, Mundler O.

World J Nucl Med. 2012 Jan;11(1):7-11. doi: 10.4103/1450-1147.98731.

6.

Radioiodine I-131 for the therapy of graves' disease.

Mumtaz M, Lin LS, Hui KC, Mohd Khir AS.

Malays J Med Sci. 2009 Jan;16(1):25-33.

7.

The evaluation and treatment of graves ophthalmopathy.

Stan MN, Garrity JA, Bahn RS.

Med Clin North Am. 2012 Mar;96(2):311-28. doi: 10.1016/j.mcna.2012.01.014. Review.

8.

Risk factors for development or deterioration of Graves' ophthalmopathy.

Stan MN, Bahn RS.

Thyroid. 2010 Jul;20(7):777-83. doi: 10.1089/thy.2010.1634. Review.

9.

Update on thyroid eye disease and management.

Bothun ED, Scheurer RA, Harrison AR, Lee MS.

Clin Ophthalmol. 2009;3:543-51.

Supplemental Content

Support Center